Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2013 2
2014 1
2015 1
2016 4
2017 9
2018 22
2019 23
2020 36
2021 24
2022 25
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Results by year

Filters applied: . Clear all
Page 1
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Routy B, et al. Among authors: mezquita l. Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2. Science. 2018. PMID: 29097494
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer.
Pradat Y, Viot J, Yurchenko AA, Gunbin K, Cerbone L, Deloger M, Grisay G, Verlingue L, Scott V, Padioleau I, Panunzi L, Michiels S, Hollebecque A, Jules-Clément G, Mezquita L, Lainé A, Loriot Y, Besse B, Friboulet L, André F, Cournède PH, Gautheret D, Nikolaev SI. Pradat Y, et al. Among authors: mezquita l. Cancer Discov. 2023 May 4;13(5):1116-1143. doi: 10.1158/2159-8290.CD-22-0966. Cancer Discov. 2023. PMID: 36862804 Free PMC article.
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Ferrara R, et al. Among authors: mezquita l. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676. JAMA Oncol. 2018. PMID: 30193240 Free PMC article.
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD. Arbour KC, et al. Among authors: mezquita l. J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20. J Clin Oncol. 2018. PMID: 30125216 Free article.
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B. Mezquita L, et al. JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771. JAMA Oncol. 2018. PMID: 29327044 Free PMC article.
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.
García-Pardo M, Czarnecka-Kujawa K, Law JH, Salvarrey AM, Fernandes R, Fan ZJ, Waddell TK, Yasufuku K, Liu G, Donahoe LL, Pierre A, Le LW, Gunasegaran T, Ghumman N, Shepherd FA, Bradbury PA, Sacher AG, Schmid S, Corke L, Feng J, Stockley T, Pal P, Rogalla P, Pipinikas C, Howarth K, Ambasager B, Mezquita L, Tsao MS, Leighl NB. García-Pardo M, et al. Among authors: mezquita l. JAMA Netw Open. 2023 Jul 3;6(7):e2325332. doi: 10.1001/jamanetworkopen.2023.25332. JAMA Netw Open. 2023. PMID: 37490292 Free PMC article. Clinical Trial.
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
Auclin E, Benitez-Montanez J, Tagliamento M, Parisi F, Gorria T, Garcia-Campelo R, Dempsey N, Pinato DJ, Reyes R, Albarrán-Artahona V, Dall'Olio F, Soldato D, Hendriks L, Nana FA, Tonneau M, Lopez-Castro R, Nadal E, Kazandjian S, Muanza T, Blanc-Durand F, Fabre E, Castro N, Arasanz H, Rochand A, Besse B, Routy B, Mezquita L. Auclin E, et al. Among authors: mezquita l. Lung Cancer. 2023 Apr;178:116-122. doi: 10.1016/j.lungcan.2023.02.002. Epub 2023 Feb 4. Lung Cancer. 2023. PMID: 36812760
Vaccine Therapy in Non-Small Cell Lung Cancer.
García-Pardo M, Gorria T, Malenica I, Corgnac S, Teixidó C, Mezquita L. García-Pardo M, et al. Among authors: mezquita l. Vaccines (Basel). 2022 May 9;10(5):740. doi: 10.3390/vaccines10050740. Vaccines (Basel). 2022. PMID: 35632496 Free PMC article. Review.
151 results